Literature DB >> 2941291

Treatment of uncomplicated gonococcal urethritis in men with two dosages of ciprofloxacin.

M J Tegelberg-Stassen, J C van der Hoek, L Mooi, J H Wagenvoort, T van Joost, M F Michel, E Stolz.   

Abstract

One hundred and sixty-four male patients suffering from urethral gonorrhoea were treated in an open randomised trial with either 250 mg (n = 85) or 500 mg (n = 79) ciprofloxacin administered in one tablet. Cure rates in both groups were 100%. Postgonococcal urethritis was observed in 31 of 85 (36%) patients in the first group, and in 21 of 79 patients (27%) in the second group. Side-effects were minor, occurring in four patients in the 250 mg group (4.7%) and in seven in the 500 mg group (8.9%). The side-effects consisted of nausea, diarrhoea and headache. Ciprofloxacin would appear to be a very effective drug in the treatment of urethral gonorrhoea in males.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2941291     DOI： 10.1007/bf02013999

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


  9 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Penicillinase-producing gonococci in the Netherlands in 1981.

Authors:  B van Klingeren; L J van Wijngaarden; M Dessens-Kroon; J D van Embden
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

3.  Antibiotic sensitivities of gonococci isolated in Rotterdam and results of treatment with cefuroxime.

Authors:  K C Nayyar; M F Michel; E Stolz
Journal:  Br J Vener Dis       Date:  1980-08

4.  Gonorrhea in Rotterdam caused by penicillinase-producing gonococci.

Authors:  K C Nayyar; R C Noble; M F Michel; E Stolz
Journal:  Br J Vener Dis       Date:  1980-08

5.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

Authors:  M Peeters; E Van Dyck; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Treatment of non-complicated urogenital, rectal and oropharyngeal gonorrhoea with intramuscular cefotaxime 1.0 g or cefuroxime 1.5 g.

Authors:  E Stolz; L Ong; T van Joost; M F Michel
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

8.  Single dose ciprofloxacin for treating gonococcal infections in men.

Authors:  P S Loo; G L Ridgway; J D Oriel
Journal:  Genitourin Med       Date:  1985-10

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191
  9 in total
  14 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Treatment of uncomplicated urogenital gonorrhoea in women with a single dose of enoxacin.

Authors:  M J Tegelberg-Stassen; A H van der Willigen; J C van der Hoek; J H Wagenvoort; H J van Vliet; B van Klingeren; T van Joost; M F Michel; E Stolz
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

3.  [Multi-step increase in resistance of Neisseria gonorrhoeae isolates after repeated in-vitro subinhibitory concentrations of second-generation quinolones].

Authors:  H C Korting; A Lukacs
Journal:  Infection       Date:  1989       Impact factor: 3.553

4.  Clinical efficacy of ciprofloxacin versus doxycycline in the treatment of non-gonococcal urethritis in males.

Authors:  A H van der Willigen; A A Polak-Vogelzang; L Habbema; J H Wagenvoort
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

5.  Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males.

Authors:  A H van der Willigen; J C van der Hoek; J H Wagenvoort; H J van Vliet; B van Klingeren; W O Schalla; J S Knapp; T van Joost; M F Michel; E Stolz
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  Quinolones in the treatment of gonorrhoea and Chlamydia trachomatis infections.

Authors:  E Stolz; J H Wagenvoort; A H van der Willigen
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

7.  Randomized comparative study of 0.5 and 1 g of cefodizime (HR 221) versus 1 g of cefotaxime for acute uncomplicated urogenital gonorrhea.

Authors:  A H van der Willigen; J H Wagenvoort; W O Schalla; J S Knapp; J M Boot; P L Heeres-Weststrate; M F Michel; B van Klingeren; E Stolz
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  P C Fuchs; A L Barry; C Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

Review 9.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

10.  In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis.

Authors:  A Nagayama; T Nakao; H Taen
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.